On the Job

Changing Lives Through Research

Innovative Colorectal Research
Targets Key Tumor-Suppressing
Molecule

Candace Caldwell and Michael Varallo

Researchers Scott Waldman, MD, PhD (left), and immunologist Adam Snook, PhD (right) have made tremendous
progress in colorectal research with the help of tissue samples provided by colorectal surgeon Scott Goldstein, MD
(center) and his surgical colleagues in colorectal surgery.

If there were a “golden ticket” in the fight
against colorectal cancer, it would be
guanylyl cyclase C (GCC) – a molecule
that plays a critical role in the suppression
of colorectal tumors. Most colorectal
tumors form or grow larger when GCC is
silenced by the hormones that regulate it.
Researchers at Jefferson are working to
find ways to manipulate these hormones
so GCC can get back to work suppressing
tumors.
Leading the efforts are clinical
pharmacologist Scott A. Waldman, MD,
PhD, and immunologist Adam Snook,
PhD, of the Waldman-Snook Laboratory.
As they study GCC and the associated
hormones, Drs. Waldman and Snook
collaborate closely with colorectal
surgeons Scott D. Goldstein, MD, FACS,
Gerald A. Isenberg, MD, FACS, and
Benjamin R. Phillips, MD, FACS, FASCRS,
as well as physicians from the Division
of Gastroenterology.
“The Department of Surgery’s
collaboration with the Waldman-Snook
Laboratory is helping to improve
outcomes and quality of life for those
coming to Jefferson for care,” says Dr.
Goldstein. “Our team is at the forefront
of innovative colorectal cancer research.”
One such project is studying how
commercially available gastrointestinal
hormones could be deployed to combat
colorectal cancer. Funded by the U.S.
Department of Defense, the study is
using tissue samples gathered by
gastroenterologists during colonoscopies
and by colorectal surgeons during
resections.

“We have mapped the mechanism
by which the hormones are lost,”
Dr. Waldman explains. “It’s a reflection of
the very first mutation in the gene APC,
which triggers the cascade of events that
leads to tumorigenesis. When APC is
mutated, a complicated signaling
mechanism shuts off the synthesis of
these hormones.” The study’s hypothesis
is that dosing patients with commercially
available hormone analogs could help
turn GCC back on, halting development
or progression of colorectal tumors.
In addition to mapping how the
hormones are lost, Drs. Waldman and
Snook want to understand the precise
signaling mechanisms that lead from
activation of GCC to the prevention of
tumor initiation and progression. Another
study is supporting that effort, and again,
Drs. Goldstein, Isenberg and Phillips are
contributing colon and rectal tissue
specimens to be studied in the lab.
The team is studying these normal and
diseased samples both in animals and
in test tubes.
“In the mice, we’re letting the tumors
grow to see if we can manipulate the
GCC and determine what signaling
mechanisms are being turned on or
off and what proteins are changing,”
Dr. Waldman says. “In the test tubes,
we’re literally creating ‘mini guts’ so
we can get a good read on what
downstream molecular pathways
are being activated by the tumorsuppressing system. We couldn’t do
any of this without our colleagues in
Colorectal Surgery.”

Last October, Candace Caldwell
made a big move—relocating from
Portland, Oregon to Philadelphia to
join the Department of Surgery. As the
Department’s first Operations Analyst,
she’s taking on a variety of evolving
responsibilities. Among them: data
analysis and reporting, expense tracking
and process improvement.

One of those friendly co-workers is
Michael Varallo, who started as the
Department’s Business Manager on
Christmas Eve 2018. It’s a role that
brought the 34-year-old South Philly
native full circle: he started working at
Jefferson at age 16 as a runner for the
Department of Surgery, a job he held
through college.

With a degree from Oregon State
University in Public Health, Health
Management and Policy, Caldwell
enjoys using data to tell a story about
current performance and identify
opportunities to improve in the future.
She said she also enjoys collaborating
with her colleagues.

After graduating from Neumann
University with a degree in Finance,
Varallo began working in Thomas
Jefferson University’s Controller’s
Office. Since then, he has moved
through progressively responsible
positions within the Jefferson enterprise.

For Caldwell, exploring a new city has
brought some surprises. For example,
she’s still adjusting to Philly weather
(Portland stays green in winter). Even
more surprising: the warmth and
friendliness of her co-workers and
neighbors.
“People warned me about an abrupt,
cold attitude,” she recalls. “But that
hasn’t happened at all. Everyone is
so nice.”

“In the test tubes, we’re
literally creating ‘mini
guts’ so we can get a good
read on what downstream
molecular pathways
are being activated by the
tumor-suppressing system.”
In addition to those studies, the
Waldman-Snook Laboratory is working
with colorectal surgeons on the second
phase of a colorectal cancer vaccine
study that showed great promise in
Phase 1. Patient enrollment will begin in
late summer or early fall. Beyond that,
Dr. Waldman says the colorectal

As Business Manager, Varallo is
responsible for planning and tracking
the Department’s budget and managing
profit-and-loss statements to ensure
revenues and costs are properly
accounted for.
Outside work, Varallo and his fiancée
are settling in to a new home in the
suburbs and planning their October
wedding. Looking to this next phase
of his life, Varallo jokes, “I’ve put myself
on a budget!”

surgeons will be highly engaged in an
upcoming study involving patients with
active metastatic disease.
“With this study, we’ll take ‘killer’ immune
cells from the patients’ own bodies and
genetically reprogram them outside the
body to recognize the specific target – in
this case, GCC being expressed on
metastatic cancer cells,” Dr. Waldman
explains. “We will create billions of those
genetically reprogrammed cells, and each
one will be a ‘smart bomb’ that ignites
when it sees a target on a cancer cell in
the lung or liver. In short, these ‘smart
bombs’ will home in on the metastatic
cancer cells but won’t harm normal lung
or liver cells.”
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